Page 58 - Read Online

Page 20 of 24 Saier et al. J Cancer Metastasis Treat 2021;7:43 https://dx.doi.org/10.20517/2394-4722.2021.87

phosphate from osteoclasts. Nat Commun 2014;5:5215. DOI PubMed PMC
72. Ryu J, Kim HJ, Chang EJ, Huang H, Banno Y, Kim HH. Sphingosine 1-phosphate as a regulator of osteoclast differentiation and
osteoclast-osteoblast coupling. EMBO J 2006;25:5840-51. DOI PubMed PMC
73. Ishii M, Kikuta J, Shimazu Y, Meier-Schellersheim M, Germain RN. Chemorepulsion by blood S1P regulates osteoclast precursor
mobilization and bone remodeling in vivo. J Exp Med 2010;207:2793-8. DOI PubMed PMC
74. Ishii T, Shimazu Y, Nishiyama I, Kikuta J, Ishii M. The role of sphingosine 1-phosphate in migration of osteoclast precursors; an
application of intravital two-photon microscopy. Mol Cells 2011;31:399-403. DOI PubMed PMC
75. Weske S, Vaidya M, Reese A, et al. Targeting sphingosine-1-phosphate lyase as an anabolic therapy for bone loss. Nat Med
2018;24:667-78. DOI PubMed
76. Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ. Regulation of bone formation by osteoclasts involves Wnt/BMP
signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A 2008;105:20764-9. DOI PubMed PMC
77. Lotinun S, Kiviranta R, Matsubara T, et al. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin
Invest 2013;123:666-81. DOI PubMed PMC
78. Bae SJ, Lee SH, Ahn SH, Kim HM, Kim BJ, Koh JM. The circulating sphingosine-1-phosphate level predicts incident fracture in
postmenopausal women: a 3.5-year follow-up observation study. Osteoporos Int 2016;27:2533-41. DOI PubMed
79. Weske S, Vaidya M, von Wnuck Lipinski K, et al. Agonist-induced activation of the S1P receptor 2 constitutes a novel osteoanabolic
therapy for the treatment of osteoporosis in mice. Bone 2019;125:1-7. DOI PubMed
80. Ogretmen B. Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer 2018;18:33-50. DOI PubMed PMC
81. Oshi M, Newman S, Tokumaru Y, et al. Intra-tumoral angiogenesis is associated with inflammation, immune reaction and metastatic
recurrence in breast cancer. Int J Mol Sci 2020;21:6708. DOI PubMed PMC
82. Kim EY, Choi B, Kim JE, Park SO, Kim SM, Chang EJ. Interleukin-22 mediates the chemotactic migration of breast cancer cells and
macrophage infiltration of the bone microenvironment by potentiating S1P/SIPR signaling. Cells 2020;9:131. DOI PubMed PMC
83. Filipenko I, Schwalm S, Reali L, et al. Upregulation of the S1P(3) receptor in metastatic breast cancer cells increases migration and
invasion by induction of PGE(2) and EP(2)/EP(4) activation. Biochimica et biophysica acta 2016;1861:1840-51. DOI PubMed
84. Stayrook KR, Mack JK, Cerabona D, et al. TGFβ-mediated induction of SphK1 as a potential determinant in human MDA-MB-231
breast cancer cell bone metastasis. Bonekey Rep 2015;4:719. DOI PubMed PMC
85. Sowder ME, Johnson RW. Bone as a preferential site for metastasis. JBMR Plus 2019;3:e10126. DOI PubMed PMC
86. Bouquerel P, Gstalder C, Müller D, et al. Essential role for SphK1/S1P signaling to regulate hypoxia-inducible factor 2α expression
and activity in cancer. Oncogenesis 2016;5:e209. DOI PubMed PMC
87. Gstalder C, Ader I, Cuvillier O. FTY720 (Fingolimod) Inhibits HIF1 and HIF2 Signaling, Promotes Vascular Remodeling, and
Chemosensitizes in Renal Cell Carcinoma Animal Model. Mol Cancer Ther 2016;15:2465-74. DOI PubMed
88. Xu Y, Dong B, Wang J, Zhang J, Xue W, Huang Y. Sphingosine kinase 1 overexpression contributes to sunitinib resistance in clear
cell renal cell carcinoma. Oncoimmunology 2018;7:e1502130. DOI PubMed PMC
89. Zhang L, Wang X, Bullock AJ, et al. Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer.
Clin Cancer Res 2015;21:1925-34. DOI PubMed PMC
90. Pal SK, Drabkin HA, Reeves JA, et al. A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with
metastatic renal cell carcinoma. Cancer 2017;123:576-82. DOI PubMed
91. Schneider G, Sellers ZP, Bujko K, Kakar SS, Kucia M, Ratajczak MZ. Novel pleiotropic effects of bioactive phospholipids in human
lung cancer metastasis. Oncotarget 2017;8:58247-63. DOI PubMed PMC
92. Ader I, Gstalder C, Bouquerel P, et al. Neutralizing S1P inhibits intratumoral hypoxia, induces vascular remodelling and sensitizes to
chemotherapy in prostate cancer. Oncotarget 2015;6:13803-21. DOI PubMed PMC
93. Brizuela L, Ader I, Mazerolles C, Bocquet M, Malavaud B, Cuvillier O. First evidence of sphingosine 1-phosphate lyase protein
expression and activity downregulation in human neoplasm: implication for resistance to therapeutics in prostate cancer. Mol Cancer
Ther 2012;11:1841-51. DOI PubMed
94. Malavaud B, Pchejetski D, Mazerolles C, et al. Sphingosine kinase-1 activity and expression in human prostate cancer resection
specimens. Eur J Cancer 2010;46:3417-24. DOI PubMed
95. Brizuela L, Martin C, Jeannot P, et al. Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to
therapeutics to bone metastasis-derived prostate cancer cells. Mol Oncol 2014;8:1181-95. DOI PubMed PMC
96. Bao Y, Guo Y, Zhang C, Fan F, Yang W. Sphingosine Kinase 1 and Sphingosine-1-Phosphate Signaling in Colorectal Cancer. Int J
Mol Sci 2017;18:2109. DOI PubMed PMC
97. Grbčić P, Sedić M. Sphingosine 1-Phosphate Signaling and Metabolism in Chemoprevention and Chemoresistance in Colon Cancer.
Molecules 2020;25:2436. DOI PubMed PMC
98. Liu SQ, Xu CY, Wu WH, et al. Sphingosine kinase 1 promotes the metastasis of colorectal cancer by inducing the
epithelialmesenchymal transition mediated by the FAK/AKT/MMPs axis. Int J Oncol 2019;54:41-52. DOI PubMed PMC
99. Bae GE, DO SI, Kim K, Park JH, Cho S, Kim HS. Increased Sphingosine Kinase 1 Expression Predicts Distant Metastasis and Poor
Outcome in Patients With Colorectal Cancer. Anticancer Res 2019;39:663-70. DOI PubMed
100. Schwiebs A, Herrero San Juan M, Schmidt KG, et al. Cancer-induced inflammation and inflammation-induced cancer in colon: a role
for S1P lyase. Oncogene 2019;38:4788-803. DOI PubMed
101. Gu X, Jiang Y, Xue W, et al. SPNS2 promotes the malignancy of colorectal cancer cells via regulating Akt and ERK pathway. Clin
Exp Pharmacol Physiol 2019;46:861-71. DOI PubMed
102. Zhang YH, Cui SX, Wan SB, Wu SH, Qu XJ. Increased S1P induces S1PR2 internalization to blunt the sensitivity of colorectal